SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Please provide your email address to receive an email when new articles are posted on . Atrial fibrillation is associated with increased risk for bleeding and stroke in patients undergoing TAVR. Left ...

Patients who had leakage to the left atrial appendage due to incomplete device sealing after left atrial appendage occlusion (LAAO) experienced more clotting and bleeding events within a year ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

A new device is helping Greeley patients with irregular heartbeats live with a reduced risk of stroke and a greater quality of life. In May, Banner Health’s North Colorado Medical Center became one of ...